Publications by authors named "T Akin Telli"
Background And Objective: The role of prostate-specific membrane antigen (PSMA)-based positron emission tomography (PET)/computed tomography (CT) in addition to magnetic resonance imaging (MRI) for local staging of prostate cancer (PC) has been poorly addressed so far. Our aim was to assess the diagnostic accuracy of PSMA PET/CT and MRI, alone and combined, for detection of extraprostatic extension (EPE) and seminal vesicle invasion (SVI) in PC.
Methods: We conducted a multicenter retrospective study evaluating patients undergoing PSMA PET/CT and MRI before radical prostatectomy.
Article Synopsis
- PSMA-PET, introduced in 2012, has significantly improved prostate cancer staging, leading to the development of the PROMISE criteria for standardized imaging reports.
- This study analyzed data from a large cohort of prostate cancer patients across multiple German hospitals to assess the prognostic value of PROMISE staging in comparison to existing clinical risk assessment models.
- The findings from 2,414 patients revealed that PPP staging had performance metrics comparable to established clinical risk scores, thus highlighting its potential usefulness in predicting overall survival outcomes.
Purpose: To assess if PSMA PET quantitative parameters are associated with pathologic ISUP grade group (GG) and upgrading/downgrading.
Methods: PCa patients undergoing radical prostatectomy with or without pelvic lymph node dissection staged with preoperative PSMA PET at seven referral centres worldwide were evaluated. PSMA PET parameters which included SUV, PSMA, and total PSMA accumulation (PSMA) were collected.
Prostate Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) is routinely used for the staging of patients with prostate cancer, but data on response assessment are sparse and primarily stem from metastatic castration-resistant prostate cancer (mCRPC) patients treated with PSMA radioligand therapy. Still, follow-up PSMA-PET is employed in earlier disease stages in case of clinical suspicion of disease persistence, recurrence or progression to decide if localized or systemic treatment is indicated. Therefore, the prognostic value of PSMA-PET derived tumor volumes in earlier disease stages (i.
View Article and Find Full Text PDFProspective results have demonstrated favorable safety and efficacy of [Lu]Lu-PSMA radiopharmaceutical therapy for up to 6 cycles in men with metastatic castration-resistant prostate cancer. However, no systematic data are available outlining the feasibility of extended therapy beyond 6 cycles. We aim to evaluate the safety and efficacy of extended [Lu]Lu-PSMA radiopharmaceutical therapy in patients who have received more than 6 cycles.
View Article and Find Full Text PDF